During the past decade, Texas Oncology-Medical City Dallas conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 16 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 6 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Oncology-Medical City Dallas" #1 sponsor was "Eli Lilly and Company" with 5 trials, followed by "Seagen Inc." with 4 trials sponsored, "Eisai Inc." with 3 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored and "Alaunos Therapeutics" with 3 trials sponsored. Other sponsors include 17 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Oncology-Medical City Dallas" #1 collaborator was "Bristol-Myers Squibb" with 2 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "Foundation Medicine" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Texas Oncology-Medical City Dallas" are "Breast Cancer" (8 trials), "Metastatic Breast Cancer" (4 trials), "Breast Neoplasms" (3 trials), "Chronic Lymphocytic Leukemia" (2 trials) and "Diffuse Large B-cell Lymphoma" (2 trials). Many other conditions were trialed in "Texas Oncology-Medical City Dallas" in a lesser frequency.

Most popular intervention types in "Texas Oncology-Medical City Dallas" are "Drug" (36 trials), "Other" (2 trials), "Device" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Abemaciclib" (4 trials), "Carboplatin" (4 trials), "Rituximab" (3 trials) and "brentuximab vedotin" (3 trials). Other intervention names were less common.

The vast majority of trials in "Texas Oncology-Medical City Dallas" are 32 trials for "All" genders, 6 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Texas Oncology-Medical City Dallas". undefined are not yet recruiting, 11 are recruiting, 11 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in Texas Oncology-Medical City Dallas, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Oncology-Medical City Dallas, 2 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".